NATCO Pharma announces launch of Carboplatin Injection, a generic version of Paraplatin in the US market by its US subsidiary

NATCO Pharma USA launches this product in manufacturing collaboration with Teyro Labs, based in Chennai. This launch helps address a critical shortage of the product in the U.S. market.

Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. Please refer to the full Prescribing Information for complete indications, limitations, and important safety information.

Carboplatin Injection had estimated sales of US$ 27.8 million in the US for 12 months ending June’26 as per industry sales data.